Pharmacologic inhibition of AR-V7 will be a valuable therapeutic strategy for patients with mCRPC. Our overall aim is to investigate the mechanism of action and determine the therapeutic potential of selective AR-V7 inhibitors in vitro and in vivo.
Perform medicinal chemistry for lead compound optimization and determine compound mechanism of action.
Investigate compound in vivo activity in CRPC xenografts and established models of enzalutamide-resistance.
Beyond promoting established PCa growth and metastasis, dysregulated UBR5 expression may play a strong role in the transformation and malignant development of the normal prostate.
To develop a novel genetically engineered mouse model (GEMM) of UBR5-driven prostate cancer. This model will be based the loss of function of the tumor suppressor Pten together with a gain of UBR5 expression.
The application of avail able statistical methods, in combination with prostate cancer PRS derivation in a population with ade quate minority population sample size, will mitigate the significant prostate-cancer PRS population port ability problems and generate a prostate cancer PRS applicable to a Black-race population.
Assessment of multi-ethnic prostate cancer PRSs
Systematic Comparison of Correction Methods
Inquiry of Population-Specific Mitigation Strategies